Use in conjunction with serum autoantibody tests to diagnose neuromyelitis optica (NMO).
Semi-Quantitative Indirect Fluorescent Antibody
Mon, Wed, Fri
Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Hemolyzed, contaminated specimens or severely lipemic specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
less than 1:1
Diagnosis of neuromyelitis optica (NMO) requires the presence of longitudinally extensive acute myelitis (lesions extending over 3 or more vertebral segments) and optic neuritis. Approximately 75 percent of patients with NMO express antibodies to the aquaporin-4 (AQP4) receptor. While the absence of AQP4 receptor antibodies does not rule out a diagnosis of NMO, presence of this antibody is diagnostic for NMO.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
If AQP4 antibody IgG is positive, then an AQP4 antibody IgG titer is reported. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|2011700||Neuromyelitis Optica/AQP4-IgG, CSF||46718-3|